Intestinal Research

CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study

Seung Yong Shin, Soo Jung Park, Young Kim, Jong Pil Im, Hyo Jong Kim, Kang-Moon Lee, Ji Won Kim, Sung-Ae Jung, Jun Lee, Sang-Bum Kang, Sung Jae Shin, Eun Sun Kim, You Sun Kim, Tae Oh Kim, Hyun-Soo Kim, Dong Il Park, Hyung Kil Kim, Eun Soo Kim, Young-Ho Kim, Do Hyun Kim, Dennis Teng, Jong-Hwa Kim, Wonyong Kim, Chang Hwan Choi,

Intest Res. 2022;20(3):350-360. Published online July 23, 2021
DOI: https://doi.org/10.5217/ir.2021.00049

Clinical Outcomes and Predictors of Response for Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis: A KASID Prospective Multicenter Cohort Study

. 2020;

Link1 Link2

Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study

Intestinal Research. 2022;20(3):350-360

Link1

Link2 Link3

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

M.F. Picco

Yearbook of Gastroenterology. 2011;2011:163-164

Link1 Link2

P530 Cost-effectiveness of vedolizumab SC vs. adalimumab for moderately to severely active ulcerative colitis

I Diakite, B Schultz, J Carter, S Snedecor, R Turpin

Journal of Crohn's and Colitis. 2020;14(Supplement_1):S454-S455

Link1

Link2

P607 Cost-effectiveness of vedolizumab IV vs. adalimumab SC for moderately to severely active ulcerative colitis

R Schultz, I Diakite, J Carter, S Snedecor, R Turpin

Journal of Crohn's and Colitis. 2020;14(Supplement_1):S508-S508

Link1

Link2

Faecal calprotectin level for assessing endoscopic activity and predicting future clinical course in patients with moderately active ulcerative colitis undergoing granulomonocytapheresis: a prospective cohort study

Takahiro Shimoyama, Takayuki Yamamoto, Satoru Umegae, Koichi Matsumoto

BMC Gastroenterology. 2018;18(1):

Link1

Link2 Link3

Su1813 COST-EFFECTIVENESS OF VEDOLIZUMAB IV VERSUS ADALIMUMAB SC FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Robert Schultz, Ibrahim Diakite, John A. Carter, Sonya Snedecor, Robin S. Turpin

Gastroenterology. 2020;158(6):S-658

Link1 Link2

Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis

D. Wolf, G. D'Haens, W. J. Sandborn, J.-F. Colombel, G. Van Assche, A. M. Robinson, A. Lazar, Q. Zhou, J. Petersson, R. B. Thakkar

Alimentary Pharmacology & Therapeutics. 2014;n/a-n/a

Link1 Link2

Correction: A multicenter retrospective study aiming to identify patients who respond well to adsorptive granulomonocytapheresis in moderately to severely active ulcerative colitis

Takayuki Yamamoto, Takayuki Iida, Kentaro Ikeya, Masaichi Kato, Ai Matsuura, Satoshi Tamura, Ryosuke Takano, Shinya Tani, Satoshi Osawa, Ken Sugimoto, Takahiro Shimoyama, Hiroyuki Hanai

Clinical and Translational Gastroenterology. 2018;9(11):e205

Link1

Link2 Link3 Link4

Correction: A multicenter retrospective study aiming to identify patients who respond well to adsorptive granulomonocytapheresis in moderately to severely active ulcerative colitis

Takayuki Yamamoto, Takayuki Iida, Kentaro Ikeya, Masaichi Kato, Ai Matsuura, Satoshi Tamura, Ryosuke Takano, Shinya Tani, Satoshi Osawa, Ken Sugimoto, Takahiro Shimoyama, Hiroyuki Hanai

Clinical and Translational Gastroenterology. 2018;9(10):e192

Link1

Link2 Link3 Link4